# Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

> **NCT03458260** · PHASE2 · COMPLETED · sponsor: **The Lymphoma Academic Research Organisation** · enrollment: 74 (actual)

## Conditions studied

- Aggressive Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Pixantrone
- **OTHER:** Ifosfamide
- **OTHER:** Etoposide
- **OTHER:** Rituximab
- **PROCEDURE:** Transplant

## Key facts

- **NCT ID:** NCT03458260
- **Lead sponsor:** The Lymphoma Academic Research Organisation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-26
- **Primary completion:** 2024-12-24
- **Final completion:** 2024-12-24
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2026-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03458260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03458260, "Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03458260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*